Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"Alemtuzumab"”.
-
Lymphodepletion with repeated cycles of alemtuzumab and secondary autoimmunity after alemtuzumab treatment of relapsing-remitting multiple sclerosis
… depleting, anti-CD52 monoclonal antibody alemtuzumab is a highly effective treatment option in RRMS, though associated with high rates of secondary autoimmune disorders. As alemtuzumab is now in routine clinical use, following licensing in Europe and the US, understanding the effects of …
-
Low-dose IL-2 for T-regulatory cell expansion after alemtuzumab therapy in relapsing-remitting multiple sclerosis
… treatment with the lymphocyte-depleting therapy alemtuzumab in patients with multiple sclerosis (RRMS)- and Treg insufficiency may be involved. In this work I: 1) tested whether low-dose IL-2 could selectively expand Tregs in this novel context; and 2) comprehensively characterised the …
-
Investigation of the role of antagonism of the Interleukin-7 Receptor in the treatment of Multiple Sclerosis in Humans and In Vitro differences between genetically stratified subjects based on Interleukin-7 Receptor Genotype
… during reconstitution of lymphocytes after Alemtuzumab treatment in MS, in which IL-7Rα plays a major role. Chapter 3 describes the prematurely aborted clinical trial of subjects with an IL-7Rα antagonist. This first-time-in-human trial demonstrated the drug was safe and well tolerated in …
-
Modeling hematologic malignancies and their treatment in humanized mice
… of a human specific monoclonal antibody to CD52, alemtuzumab, which is currently approved for treatment of chronic lymphocytic leukemia, but not ALL. Alemtuzumab treatment of secondary mice resulted in an almost complete clearance of leukemic blasts from the periphery and a significant improvement …
-
Imaging and therapy in multiple sclerosis
… treatment with fingolimod, natalizumab or alemtuzumab was associated with a lower risk of conversion to SPMS compared to initial treatment with glatiramer acetate or interferon beta over a median 5.8 years of follow-up. A lower risk of conversion was also associated with early (versus late) …
-
Immunogeneic Cell Populations of the Skin
… be the use of DC specific monoclonal antibodies. Alemtuzumab (anti-CD52) is a monoclonal antibody and has proven effective in preventing aGvHD after aHSCT. It may, despite depleting donor T cells, also work by targeting recipient DCs. To determine whether the last mechanism of action is …